Oxford Science Enterprises
About
Oxford Science Enterprises Oxford Science Enterprises was founded in 2015 as an independent investment company with a unique partnership with the University of Oxford. The firm manages £1.1B and secured a £175M NAV financing facility from Deutsche Bank and Goldman Sachs in March 2025 to support further growth. The core portfolio consists of roughly 40 companies across life sciences, health tech, and deep tech. The headline achievement is Vaccitech, which co-invented the Oxford/AstraZeneca COVID
Industries
Stage focus
SeedSeries A
Geography
UKEurope
Notable investments
- Vaccitech
- First Light Fusion
- ORCA Computing
- Base Genomics
- OMass Therapeutics
Raising from Oxford Science Enterprises?
I've worked with founders across the industrial stack. If Oxford Science Enterprises is on your list, I can help you map the introduction path, sharpen the narrative, and run a tight process.
Talk to Dan